semaglutide intestinal paralysis class action in kentucky Novo Nordisk sues Eli Lilly for false advertising over weight loss drug comparisons. Get the details semaglutide bowel obstruction class action

Failure to Adequately Warn Patients About Known Risks The master complaint filed in MDL 3094 alleges that Novo Nordisk and Eli Lilly knew or should have known about the severe gastroparesis and vision loss risks associated with their GLP-1 medications but failed to provide adequate warnings on product labels, marketing materials, or prescribing information

Here's what the brand's own product pages say about each option: Compounded Semaglutide - from $149/month, "up to 20% weight loss," per the dedicated product page Compounded Tirzepatide - from $187/month, "up to 25% weight loss," per the dedicated product page Worth flagging directly: Zevay's general GLP-1 landing page shows a third figure - "From $199/month" alongside the same "up to 25%" claim - that matches neither dedicated product page

Medicines like Mounjaro and Ozempic have gained popularity for their ability to control blood sugar, alongside aiding weight loss

it reduces apoptosis by decreasing the phosphorylation of Ser46 (Zhang et al., 2018)